Catalyst Pharmaceuticals Announces Firdapse® (amifampridine) New Drug Application Continues Under Review

FDA PDUFA goal date remains tomorrow, November 28, 2018

CORAL GABLES, Fla., Nov. 27, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with respect to the company’s new drug application for Firdapse. The company reported that a contractor working on a web page unintentionally allowed a live screen to be seen that reflected that the possible approval of the company’s NDA had already been received.

The company is issuing this release in order to clarify to the marketplace the status of its NDA.

CONTACT: Investor Contact
Brian Korb
Solebury Trout 
(646) 378-2923
[email protected]

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
[email protected]

Media Contact
David Schull
Russo Partners
(212) 845-4271
[email protected]